Fox Run Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Fox Run Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-449	Closed	-$204K	–	1265
2025 Q4	$204K	Sell	449 -167	-27%	-$72K	0.03%	802
2025 Q3	$241K	Buy	+616	New	+$257K	0.04%	753
2025 Q2	–	Sell	-1,330	Closed	-$645K	–	1276
2025 Q1	$645K	Buy	+1,330	New	+$620K	0.1%	379
2024 Q3	–	Sell	-586	Closed	-$275K	–	1127
2024 Q2	$275K	Buy	+586	New	+$254K	0.05%	573
2023 Q1	–	Sell	-2,578	Closed	-$744K	–	951
2022 Q4	$744K	Buy	2,578 +1,372	+114%	+$418K	0.3%	62
2022 Q3	$349K	Buy	+1,206	New	+$347K	0.14%	302
2022 Q1	–	Sell	-1,636	Closed	-$359K	–	722
2021 Q4	$359K	Buy	+1,636	New	+$318K	0.21%	168
2020 Q1	–	Sell	-1,044	Closed	-$229K	–	377
2019 Q4	$229K	Buy	+1,044	New	+$211K	0.18%	289
2018 Q4	–	Sell	-2,530	Closed	-$488K	–	749
2018 Q3	$488K	Buy	+2,530	New	+$451K	0.21%	180
2018 Q1	–	Sell	-4,084	Closed	-$612K	–	946
2017 Q4	$612K	Buy	+4,084	New	+$605K	0.18%	210
2017 Q3	–	Sell	-4,800	Closed	-$619K	–	886
2017 Q2	$619K	Buy	+4,800	New	+$578K	0.21%	149
2016 Q4	–	Sell	-5,600	Closed	-$488K	–	691
2016 Q3	$488K	Buy	+5,600	New	+$529K	0.29%	113
2016 Q2	–	Sell	-8,600	Closed	-$684K	–	682
2016 Q1	$684K	Buy	+8,600	New	+$778K	0.46%	33

Other funds holding VRTX

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Fox Run Management's VRTX Position: Q1 2026 in Review

Fox Run Management sold out of Vertex Pharmaceuticals (VRTX) in Q1 2026, closing a stake of 449 shares — an estimated $204K sold.

Fox Run Management first reported a position in VRTX in Q1 2016 and held it in 13 quarters. The position peaked at $744K in Q4 2022. 1,697 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

Fox Run Management reported no remaining Vertex Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Fox Run Management sold 449 Vertex Pharmaceuticals shares in Q1 2026, an estimated $204K.
Fox Run Management first reported a position in Vertex Pharmaceuticals in Q1 2016 and held it in 13 quarters.
Fox Run Management's Vertex Pharmaceuticals position peaked at $744K in Q4 2022.
1,697 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Fox Run Management's 13F filing for Q1 2026, filed 12 May 2026.